Last reviewed · How we verify
Existing depression medication treatment
Existing depression medication treatment is a Small molecule drug developed by Centre for Addiction and Mental Health. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Existing depression medication treatment |
|---|---|
| Sponsor | Centre for Addiction and Mental Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Overdose Prevention Centers and Behavioral Health
- Bridging the Gap: Implementing BRIDGES (NA)
- Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease (NA)
- Investigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders
- Development and Evaluation of a CBT-based Transdiagnostic Transcultural Web App for Mental Health Problems (NA)
- Effectiveness of an Evidence-based Stepped Care System for Alcohol and Other Drug Use Problems Among Congolese Refugees in Zambia (NA)
- Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors (NA)
- Personalized Indications for CBT and Antidepressants in Treating Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Existing depression medication treatment CI brief — competitive landscape report
- Existing depression medication treatment updates RSS · CI watch RSS
- Centre for Addiction and Mental Health portfolio CI
Frequently asked questions about Existing depression medication treatment
What is Existing depression medication treatment?
Who makes Existing depression medication treatment?
What development phase is Existing depression medication treatment in?
Related
- Manufacturer: Centre for Addiction and Mental Health — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing